In the last trading session, 1.14 million shares of the Inozyme Pharma Inc (NASDAQ:INZY) were traded, and its beta was 2.07. Most recently the company’s share price was $3.96, and it changed around $0.0 or 0.00% from the last close, which brings the market valuation of the company to $255.66M. INZY currently trades at a discount to its 52-week high of $6.24, offering almost -57.58% off that amount. The share price’s 52-week low was $0.72, which indicates that the current value has risen by an impressive 81.82% since then.
Inozyme Pharma Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.75. If we narrow it down even further, the data shows that 0 out of 16 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 7 recommended INZY as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight.
Inozyme Pharma Inc (NASDAQ:INZY) trade information
The performance over the last five days has remained in the green territory. The rise to weekly highs of 3.99 on recent trading dayincreased the stock’s daily price by 0.75%. The company’s shares are currently up 42.96% year-to-date, but still up 0.25% over the last five days. On the other hand, Inozyme Pharma Inc (NASDAQ:INZY) is 312.50% up in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $4, which translates to bulls needing to increase their stock price by 1.0% from its current value. Analyst projections state that INZY is forecast to be at a low of $4 and a high of $4.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -13.98%. Inozyme Pharma Inc earnings are expected to increase by 11.66% in 2025, but the outlook is positive 21.72% per year for the next five years.
INZY Dividends
Inozyme Pharma Inc’s next quarterly earnings report is expected to be released in June.
PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC, with 7.2563% or 4.49 million shares worth $20.05 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 2.22 shares worth $8.79 million, making up 3.44% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held roughly 1.56 shares worth around $6.17 million, which represents about 2.41% of the total shares outstanding.
